Blood test may personalize esophageal cancer therapy

NCT ID NCT06792786

Recruiting now Disease control Sponsor: The Central Hospital of Lishui City Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether monitoring tumor DNA in the blood (ctDNA) can help guide treatment for esophageal cancer. Researchers will give patients immunotherapy and chemotherapy, followed by chemoradiotherapy, and track ctDNA levels to see if they predict outcomes. The goal is to improve survival for people with advanced esophageal cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Toripalimab, paclitaxel, cisplatin
What this could lead to: If successful, this approach could lead to more personalized and effective treatment for esophageal cancer, potentially improving survival rates.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The treatment involves chemotherapy and immunotherapy, which can cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CTDNA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CTDNA ESOPHAGEAL CANCER

Contacts and locations

Locations

Jinhua Municipal Central Hospital
RECRUITING

Jinhua, Zhejiang, 321000, China
The central Hospital of Lishui City
RECRUITING

Lishui, Zhejiang, 323000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.